Tandem Diabetes Care (TD5A) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TD5A Analyst Ratings

Moderate Buy

10 Buy

6 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Tandem

Diabetes Care

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TD5A Stock 12 Month Forecast

Average Price Target

€26.75

▲(57.35% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is €26.75 with a high forecast of €48.13 and a low forecast of €13.56. The average price target represents a 57.35% change from the last price of €17.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"€9","19":"€19","29":"€29","39":"€39","49":"€49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48.130607250000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€48.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.748949605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.564080225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,19,29,39,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.2,15.886969788461538,18.573939576923078,21.260909365384617,23.947879153846156,26.634848942307695,29.321818730769234,32.00878851923078,34.695758307692316,37.382728096153855,40.069697884615394,42.75666767307693,45.44363746153847,{"y":48.130607250000004,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.2,14.242226892692306,15.284453785384615,16.326680678076922,17.36890757076923,18.411134463461536,19.453361356153845,20.495588248846154,21.53781514153846,22.580042034230768,23.622268926923077,24.664495819615382,25.70672271230769,{"y":26.748949605,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.2,13.228006171153845,13.256012342307692,13.284018513461538,13.312024684615384,13.34003085576923,13.368037026923076,13.396043198076923,13.424049369230769,13.452055540384615,13.480061711538461,13.508067882692307,13.536074053846153,{"y":13.564080225,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.155,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.515,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.535,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.665,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.475,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€48.13

Average Price Target€26.75

Lowest Price Target€13.56

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanne Wuensch

Citi

€14.88

Hold

-12.49%

Downside

Reiterated

07/08/26

Citi Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)

Unknown Analyst

Deutsche Bank

Not Ranked

Deutsche Bank

€13.56

Hold

-20.21%

Downside

Initiated

06/23/26

Tandem Diabetes initiated with a Hold at Deutsche BankTandem Diabetes initiated with a Hold at Deutsche Bank

Travis Steed

Bank of America Securities

€21.88

Hold

28.69%

Upside

Reiterated

06/08/26

Tandem Diabetes: Neutral Stance Maintained as Mobi Tubeless Opportunity Balances Execution Risks; $25 Price Target Unchanged

Larry Biegelsen

Wells Fargo

€18.38→€23.63

Buy

38.99%

Upside

Upgraded

06/01/26

Tandem Diabetes upgraded to Overweight from Equal Weight at Wells FargoTandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo

David Roman

Goldman Sachs

€21→€18.38

Hold

8.10%

Upside

Reiterated

05/27/26

Tandem Diabetes price target lowered to $21 from $24 at Goldman SachsTandem Diabetes price target lowered to $21 from $24 at Goldman Sachs

Richard Newitter

Truist Financial

€30.63→€27.13

Buy

59.58%

Upside

Reiterated

05/11/26

Truist Financial Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)

Bruce Jackson

Benchmark Co.

―

Hold

―

Initiated

05/11/26

Tandem Diabetes initiated with a Hold at BenchmarkTandem Diabetes initiated with a Hold at Benchmark

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

€19.25

Buy

13.25%

Upside

Reiterated

05/08/26

Oppenheimer Remains a Buy on Tandem Diabetes Care (TNDM)

Anthony Petrone

Mizuho Securities

€19.25→€21

Hold

23.54%

Upside

Reiterated

05/08/26

Tandem Diabetes price target raised to $24 from $22 at MizuhoTandem Diabetes price target raised to $24 from $22 at Mizuho

Mathew Blackman

TD Cowen

€24.5

Buy

44.13%

Upside

Reiterated

05/08/26

Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained

Matt Miksic

Barclays

€49.01→€48.13

Buy

183.12%

Upside

Reiterated

05/08/26

Tandem Diabetes Care (TNDM) Gets a Buy from Barclays

William Plovanic

Canaccord Genuity

€30.63

Buy

80.17%

Upside

Reiterated

05/08/26

Analyst Reiterates Buy on Tandem, Maintains $35 Price Target Amid Transformation and Margin Expansion Prospects

Frank Takkinen

Lake Street

€43.76

Buy

157.38%

Upside

Reiterated

05/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matthew O'Brien

Piper Sandler

€28.88

Buy

69.87%

Upside

Reiterated

05/08/26

Tandem Diabetes Care (TNDM) Gets a Buy from Piper Sandler

Shagun Singh Chadha

RBC Capital

€26.25

Buy

54.43%

Upside

Reiterated

05/07/26

Tandem Diabetes Care (TNDM) Receives a Buy from RBC Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanne Wuensch

Citi

€14.88

Hold

-12.49%

Downside

Reiterated

07/08/26

Citi Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)

Unknown Analyst

Deutsche Bank

Not Ranked

Deutsche Bank

€13.56

Hold

-20.21%

Downside

Initiated

06/23/26

Tandem Diabetes initiated with a Hold at Deutsche BankTandem Diabetes initiated with a Hold at Deutsche Bank

Travis Steed

Bank of America Securities

€21.88

Hold

28.69%

Upside

Reiterated

06/08/26

Tandem Diabetes: Neutral Stance Maintained as Mobi Tubeless Opportunity Balances Execution Risks; $25 Price Target Unchanged

Larry Biegelsen

Wells Fargo

€18.38→€23.63

Buy

38.99%

Upside

Upgraded

06/01/26

Tandem Diabetes upgraded to Overweight from Equal Weight at Wells FargoTandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo

David Roman

Goldman Sachs

€21→€18.38

Hold

8.10%

Upside

Reiterated

05/27/26

Tandem Diabetes price target lowered to $21 from $24 at Goldman SachsTandem Diabetes price target lowered to $21 from $24 at Goldman Sachs

Richard Newitter

Truist Financial

€30.63→€27.13

Buy

59.58%

Upside

Reiterated

05/11/26

Truist Financial Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)

Bruce Jackson

Benchmark Co.

―

Hold

―

Initiated

05/11/26

Tandem Diabetes initiated with a Hold at BenchmarkTandem Diabetes initiated with a Hold at Benchmark

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

€19.25

Buy

13.25%

Upside

Reiterated

05/08/26

Oppenheimer Remains a Buy on Tandem Diabetes Care (TNDM)

Anthony Petrone

Mizuho Securities

€19.25→€21

Hold

23.54%

Upside

Reiterated

05/08/26

Tandem Diabetes price target raised to $24 from $22 at MizuhoTandem Diabetes price target raised to $24 from $22 at Mizuho

Mathew Blackman

TD Cowen

€24.5

Buy

44.13%

Upside

Reiterated

05/08/26

Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained

Matt Miksic

Barclays

€49.01→€48.13

Buy

183.12%

Upside

Reiterated

05/08/26

Tandem Diabetes Care (TNDM) Gets a Buy from Barclays

William Plovanic

Canaccord Genuity

€30.63

Buy

80.17%

Upside

Reiterated

05/08/26

Analyst Reiterates Buy on Tandem, Maintains $35 Price Target Amid Transformation and Margin Expansion Prospects

Frank Takkinen

Lake Street

€43.76

Buy

157.38%

Upside

Reiterated

05/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matthew O'Brien

Piper Sandler

€28.88

Buy

69.87%

Upside

Reiterated

05/08/26

Tandem Diabetes Care (TNDM) Gets a Buy from Piper Sandler

Shagun Singh Chadha

RBC Capital

€26.25

Buy

54.43%

Upside

Reiterated

05/07/26

Tandem Diabetes Care (TNDM) Receives a Buy from RBC Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tandem Diabetes Care

3 Months

Jeff JohnsonRobert W. Baird

Success Rate

10/17 ratings generated profit

Average Return

+55.63%

Copying Jeff Johnson's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +55.63% per trade.

1 Year

Jeff JohnsonRobert W. Baird

Success Rate

10/17 ratings generated profit

Average Return

+91.48%

Copying Jeff Johnson's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +91.48% per trade.

2 Years

Jeff JohnsonRobert W. Baird

Success Rate

10/17 ratings generated profit

Average Return

+89.83%

Copying Jeff Johnson's trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +89.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TD5A Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TD5A has received 9 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. TD5A average Analyst price target in the past 3 months is 26.75.

Each month's total comprises the sum of three months' worth of ratings.

TD5A Financial Forecast

TD5A Earnings Forecast

Next quarter’s earnings estimate for TD5A is -€0.29 with a range of -€0.38 to -€0.20. The previous quarter’s EPS was -€0.26. TD5A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year TD5A has Performed in-line its overall industry.

TD5A Sales Forecast

Next quarter’s sales forecast for TD5A is €222.70M with a range of €219.26M to €225.06M. The previous quarter’s sales results were €216.02M. TD5A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year TD5A has Performed in-line its overall industry.

TD5A Stock Forecast FAQ

What is DE:TD5A’s average 12-month price target, according to analysts?

Based on analyst ratings, Tandem Diabetes Care’s 12-month average price target is 26.75.

What is DE:TD5A’s upside potential, based on the analysts’ average price target?

Tandem Diabetes Care has 57.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Tandem Diabetes Care a Buy, Sell or Hold?

Tandem Diabetes Care has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 6 hold ratings and 0 sell ratings.

What is Tandem Diabetes Care’s share price target?

The average share price target for Tandem Diabetes Care is 26.75. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €48.13 ,and the lowest forecast is €13.56. The average share price target represents 57.35% Increase from the current price of €17.

What do analysts say about Tandem Diabetes Care?

Tandem Diabetes Care’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Tandem Diabetes Care?

To buy shares of DE:TD5A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Tandem Diabetes Care (TD5A) Stock Forecast & Price Target

TD5A Analyst Ratings

TD5A Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tandem Diabetes Care

TD5A Analyst Recommendation Trends

TD5A Financial Forecast

TD5A Earnings Forecast

TD5A Sales Forecast

TD5A Stock Forecast FAQ

Detailed List of Analyst Forecasts